On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Previously, EGFR mutation-positive NSCLC patients relied on chemotherapy to prevent cancer recurrence after surgery, according to the foundation. “I am pleased we have been able to recommend ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.